<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043380</url>
  </required_header>
  <id_info>
    <org_study_id>UMIN000002959</org_study_id>
    <nct_id>NCT01043380</nct_id>
  </id_info>
  <brief_title>Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound</brief_title>
  <acronym>PRECISE-IVUS</acronym>
  <official_title>Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kumamoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kumamoto University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the difference in the effect of coronary plaque
      regression (as measured by intravascular ultrasound [IVUS] imaging) between cholesterol
      absorption inhibitor and cholesterol synthesis inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change from baseline to follow-up in percent atheroma volume (PAV) in the target lesion</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline (before randomization) to follow-up (9-12 months after randomization) in the atheroma volume</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percentage change from baseline to follow-up in the minimum lumen diameter (MLD) and percent diameter stenosis (%DS)</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage changes from baseline to follow-up in serum lipids</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between regression of coronary plaque and serum lipids profiles</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hs-CRP from baseline to follow-up</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between regression of coronary plaque and inflammatory markers (white blood cell count and hs-CRP)</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percentage change from baseline to follow-up in the PV of the PCI target lesion</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percentage change from baseline to follow-up in the MLD and %DS of the PCI target lesion</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE (cardiac death, non-fatal Q wave and/or non-Q wave myocardial infarction, target vessel revascularization [percutaneous coronary intervention or coronary artery bypass grafting])</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Adverse events, subjective symptoms/objective findings, physical tests), blood tests [hematology, clinical chemistry, glucose metabolism test], urinalysis)</measure>
    <time_frame>before randomization &amp; 9-12 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>LZ group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]</intervention_name>
    <description>Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.</description>
    <arm_group_label>LZ group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipitor (Atorvastatin) monotherapy</intervention_name>
    <description>The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.</description>
    <arm_group_label>L group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent,

          -  30 to 85 years old,

          -  Plan to undergo PCI and LDL-C &gt;= 100 mg/dL

        Exclusion Criteria:

          -  Familial hypercholesterolemia

          -  Being treated with Zetia (Ezetimibe)

          -  Being treated with Fibrates

          -  Renal insufficiency (serum creatinine &gt;= 2.0 mg/dl)

          -  Altered hepatic function (serum aspartate aminotransferase or alanine aminotransferase
             &gt;= 3-folds of standard value in each institute)

          -  Undergoing hemodialysis or peritoneal dialysis

          -  Allergic to Lipitor and/or Zetia

          -  Severe underlying disease

          -  Lack of decision-making capacity

          -  Recognized as inadequate by attending doctor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisao Ogawa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kumamoto University, Graduate School of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kumamoto University</name>
      <address>
        <city>Kumamoto</city>
        <zip>8608556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kumamoto University</investigator_affiliation>
    <investigator_full_name>Hisao Ogawa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Heart Diseases</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Ezetimibe</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Dyslipidemias</keyword>
  <keyword>Intravascular Ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

